Bayer's Raised Guidance Comes With an Asterisk as Legal Bills Keep the Cash Register Ringing

Bayer shares jumped 7.6% to EUR 53.70 on Tuesday after the German drugs-to-seeds group lifted its full-year outlook on the back of a stronger third quarter. Yet the rally papers over a more awkward truth: the improvement is concentrated almost entirely in one division, the cash flow is still bleeding, and at least one prominent analyst suspects the headline beat owes something to one-off items.

Jefferies' Michael Leuchten kept his "Hold" rating and EUR 46 price target unchanged, pointing to disposals of non-core businesses and lower inventory write-downs as factors that may have flattered adjusted operating profit. Adjusted earnings per share, meanwhile, came in below expectations — a reminder that the better operating numbers have not flowed through to shareholders in full.

Pharma carries the quarter

The engine behind the surprise was the pharmaceuticals unit, where Nubeqa and Kerendia drove growth and offset weakness in agriculture. EBITDA before special items for the division climbed 23.6% to EUR 1.292 billion, while currency- and portfolio-adjusted sales rose 6.4%. Group EBITDA before special items reached EUR 1.615 billion, up 6.9% and ahead of consensus. Chief executive Bill Anderson, quoted by Handelsblatt, called the pharma performance a "turning point."

Not everyone shares Jefferies' caution. BofA Global Research argues the market massively underestimates the pharma unit's potential and points to multi-year cash flow prospects. The split between the two houses comes down to durability: Jefferies frets about special effects, BofA about the long game.

A higher bar for 2026

Bayer now expects currency-adjusted EBITDA before special items of EUR 9.8 billion to EUR 10.3 billion for 2026, raising its previous guidance. The pharma division's EBITDA margin is pencilled in at 25% to 27%, with sales growth seen at the upper end of the forecast range. That upgrade matters because it signals the group expects the stronger trend to feed through to the full year, rather than being a one-quarter wonder.

What the rosier outlook does not fix is the balance sheet. Free cash flow for the full year is still expected to be negative, now guided to between minus EUR 1.5 billion and minus EUR 0.5 billion — an improvement, but a outflow nonetheless. Litigation remains the chief drain: Reuters reports Bayer expects around EUR 5 billion of outflows in 2026 for settlements, judgments and legal fees. Operating recovery and financial relief, in other words, remain two separate stories.

A mixed picture below the surface

Within the operating business, the divergence is stark. Crop Science's EBITDA before special items fell 41.3%, and Consumer Health slipped 4.4%. The group posted a net loss of EUR 672 million. A higher annual forecast therefore sits alongside an uneven earnings profile, and the real test is whether Bayer can sustain the pharma upswing without comparable one-offs while containing the drag from its other units. Jefferies' reticence targets precisely that gap between a strong adjusted operating result and a recovery that is not yet broadly supported.

The legal backdrop has also shifted. A Missouri jury on Friday unanimously rejected claims from three women who blamed Roundup for their cancers — the first Roundup trial win for subsidiary Monsanto since the US Supreme Court's Durnell decision, according to Reuters. Leuchten called the courtroom success encouraging but stopped short of changing his stance. JPMorgan's Richard Vosser was more upbeat, calling the verdict a further step towards containing the litigation and reiterating "Overweight" with a EUR 61 target; he anticipated a positive share price reaction, though the note carried no new upgrade. Judicial approval of Bayer's glyphosate settlement programme was still outstanding as of Friday, Jefferies noted.

Pipeline news adds colour

Away from the courtroom, Bayer has had a run of regulatory and clinical updates. Roughly a week ago China's NMPA approved Asundexian under the brand name Sunharbo to reduce stroke risk in adults after a non-cardioembolic ischaemic stroke or high-risk TIA, based on the Phase III OCEANIC-STROKE trial. About a fortnight earlier, an interim analysis of DASL-HiCaP showed darolutamide combined with androgen deprivation and radiotherapy cut the risk of metastases or death by 58% versus placebo, with four-year metastasis-free survival of 95% against 88%.

Bayer published its quarterly statement and third-quarter 2026 results at 7:30 CET, with an investor video call scheduled for 14:00 CET.